Ballew Advisors’s Gilead Sciences GILD Stock Holding History

Ballew Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-78	Closed	-$5K	–	224
2018 Q3	$5K	Buy	+78	New	+$5.89K	﹤0.01%	352

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ballew Advisors's GILD Position: Q4 2018 in Review

Ballew Advisors sold out of Gilead Sciences (GILD) in Q4 2018, closing a stake of 78 shares — an estimated $5K sold.

Ballew Advisors first reported a position in GILD in Q3 2018 and held it in 1 quarter. The position peaked at $5K in Q3 2018. 1,496 funds tracked by Wall St. Rank hold GILD as of Q4 2018.

Ballew Advisors reported no remaining Gilead Sciences position as of Q4 2018 after selling out during the quarter.
Ballew Advisors sold 78 Gilead Sciences shares in Q4 2018, an estimated $5K.
Ballew Advisors first reported a position in Gilead Sciences in Q3 2018 and held it in 1 quarter.
Ballew Advisors's Gilead Sciences position peaked at $5K in Q3 2018.
1,496 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2018.

Based on Ballew Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.